<SEC-DOCUMENT>0001640334-19-000238.txt : 20190213
<SEC-HEADER>0001640334-19-000238.hdr.sgml : 20190213
<ACCEPTANCE-DATETIME>20190213164416
ACCESSION NUMBER:		0001640334-19-000238
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190211
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190213
DATE AS OF CHANGE:		20190213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inmune Bio, Inc.
		CENTRAL INDEX KEY:			0001711754
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475205835
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38793
		FILM NUMBER:		19598112

	BUSINESS ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		8589643720

	MAIL ADDRESS:	
		STREET 1:		1224 PROSPECT STREET
		STREET 2:		SUITE 150
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>inmune_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title>inmune_8k.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><b style="MARGIN: 0px"> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"><font size="2"></font></div> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"><font size="2"></font></div></td></tr></table> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0"> <tr> <td> <p style="MARGIN: 0px" align="center"><b><font size="3">UNITED STATES<br></font><font size="3">SECURITIES AND EXCHANGE COMMISSION</font> <br><font size="3">Washington, D.C. 20549</font></b></p></td></tr></table></p>&nbsp;</b>&nbsp; <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="5">FORM 8-K</font></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>CURRENT REPORT</b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center">Date of Report (Date of earliest event reported): February 11, 2019</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="60%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="5">INMUNE BIO INC.</font></b></p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px 0px 0px 0in" align="center">(Exact name of registrant as specified in charter)</p></td></tr></table> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Nevada</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>001-38793</b></p></td> <td valign="top" width="5%"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>47-5205835</b></p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">(State or other jurisdiction</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">(Commission</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">(IRS Employer</p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">of incorporation)</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">File Number)</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">Identification No.)</p></td></tr></table> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><u>1224 Prospect Street, Suite 150, La Jolla, CA 92037</u></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">(Address of Principal Executive Offices) (Zip Code)</p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><u>(858) 964 3720</u></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">(Registrant&#8217;s Telephone Number, Including Area Code)</p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><u>Not Applicable</u></b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">(Former Name or Former Address, If Changed Since Last Report)</p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u>&nbsp;General Instruction A.2. below):</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td valign="top" width="4%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><font style="FONT-FAMILY: Wingdings"><font style="FONT-FAMILY: Wingdings" face="Times New Roman">&#168;</font></font></p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><font style="FONT-FAMILY: Wingdings"><font style="FONT-FAMILY: Wingdings" face="Times New Roman">&#168;</font></font></p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><font style="FONT-FAMILY: Wingdings"><font style="FONT-FAMILY: Wingdings" face="Times New Roman">&#168;</font></font></p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><font style="FONT-FAMILY: Wingdings"><font style="FONT-FAMILY: Wingdings" face="Times New Roman">&#168;</font></font></p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">Emerging growth company&nbsp;<font style="FONT-FAMILY: Wingdings">x</font></p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<font style="FONT-FAMILY: Wingdings"><font style="FONT-FAMILY: Wingdings" face="Times New Roman">&#168;</font></font></p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p> <p style="MARGIN: 0px"> <table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px"><b>Item 7.01 Regulation FD Disclosure</b></p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 33.75pt">On February 11, 2019, the INmune Bio, Inc. (the &#8220;Company&#8221;) issued a press release announcing that the Company has been awarded a grant to receive $1,000,000 from the Alzheimer's Association to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer&#8217;s disease. The endowment was awarded under the Part the Cloud to RESCUE grant. The $1,000,000 award will be paid to the Company in tranches over the course of the Phase 1 clinical trial. A copy of the press release is attached hereto and incorporated herein by reference in its entirety as&nbsp;<u>Exhibit 99.1</u>.</p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><b>Item 9.01 Financial statements and Exhibits</b></p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in">(d) Exhibits.</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="10%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>Exhibit Number</b></p></td> <td valign="top" width="2%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>Description</b></p></td></tr> <tr height="15" bgcolor="#cceeff"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><a href="inmune_ex991.htm">99.1</a></p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><a href="inmune_ex991.htm">Press release dated February 11, 2019</a></p></td></tr></table> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"> <table id="pagebreakbe06e66b-bc9f-43ee-a055-5ddaaeae2171" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">&nbsp;2</p></td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>SIGNATURE</b></p> <p style="MARGIN: 0px 0px 0px 0in" align="center">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 33.75pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="MARGIN: 0px">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td> <td valign="top" colspan="2"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>INMUNE BIO INC.</b></p></td> <td></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top" colspan="2"></td> <td> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td></tr> <tr height="15"> <td valign="top" width="50%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Date: February 13, 2019</p></td> <td valign="top" width="3%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">By:</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="35%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><i>/s/ David Moss</i></p></td> <td width="12%"></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">David Moss</p></td> <td></td></tr> <tr height="15"> <td valign="top"></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Chief Financial Officer</p></td> <td></td></tr></table> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">&nbsp;3</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>inmune_ex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head><title>inmune_ex991.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b>EXHIBIT 99.1</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><font size="5" face="Arial">INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimer&#8217;s Disease</font></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><i><font face="Arial">The Alzheimer&#8217;s Association awarded INmune Bio the Part the Cloud to RESCUE grant to target neuroinflammation in Alzheimer&#8217;s Disease</font></i></p> <p style="MARGIN: 0px"><font face="Arial">&nbsp;</font></p> <p style="MARGIN: 0px 0px 0px 0in"><font face="Arial">LA JOLLA, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) --&nbsp;<font color="#7ac142">INmune Bio, Inc.&nbsp;</font><u>(NASDAQ: INMB),</u> an immunotherapy company focused on developing treatments that harness the patient&#8217;s innate immune system to fight disease, today announced that it has been awarded a grant to receive $1,000,000 from the&nbsp;<font color="#7ac142">Alzheimer's Association&nbsp;</font>to advance XPro1595, a novel therapy targeting neuroinflammation as a cause of Alzheimer&#8217;s disease. The endowment was awarded under the&nbsp;<font color="#7ac142">Part the Cloud to RESCUE&nbsp;</font>grant. The $1,000,000 award will be paid to the Company in traches over the course of the Phase 1 clinical trial.</font></p> <p style="MARGIN: 0px"><font face="Arial">&nbsp;</font></p> <p style="MARGIN: 0px 0px 0px 0in"><font face="Arial">&#8220;We are honored to receive this grant from the Alzheimer&#8217;s Association,&#8221; said RJ Tesi, M.D., CEO of INmune Bio. &#8220;The Alzheimer&#8217;s Association has shown the vision and leadership to support the quest for effective therapies beyond traditional targets. As an immunology company, we focus on the role that innate immune dysregulation and neuroinflammation play in the progression of Alzheimer&#8217;s. This grant allows us to enter clinical trials &#8211; something that would not have been possible without the organization&#8217;s generous support.&#8221;</font></p> <p style="MARGIN: 0px"><font face="Arial">&nbsp;</font></p> <p style="MARGIN: 0px 0px 0px 0in"><font face="Arial">&#8220;Today, 50 million people worldwide are living with Alzheimer&#8217;s and related dementias, a truly astounding number that continues to grow with the aging global population,&#8221; said CJ Barnum, Ph.D., Director of Neuroscience for INmune Bio. &#8220;XPro1595 has been shown to inhibit microglial activation, part of the pathophysiology of neuroinflammation, in animal models of neurodegenerative disease. This Phase I trial will translate those findings into patients.&#8221; For more information about the Part the Cloud grants, please visit:&nbsp;<font color="#7ac142">http://www.alz.org/partthecloud/overview.asp</font></font></p> <p style="MARGIN: 0px"><font face="Arial">&nbsp;</font></p> <p style="MARGIN: 0px 0px 0px 0in"><font face="Arial">For more information about the Alzheimer&#8217;s Association, please visit: <font color="#7ac142">http://www.alz.org/</font></font></p> <p style="MARGIN: 0px"><font face="Arial">&nbsp;</font></p> <p style="MARGIN: 0px 0px 0px 0in"><font face="Arial"><b>About INmune Bio, Inc.</b> INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient&#8217;s innate immune system&#8217;s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient&#8217;s NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells (MDSC), which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio&#8217;s product platforms target residual disease and utilize a precision medicine approach for treatment of a wide variety of hematologic malignancies and solid tumors. To learn more, please visit&nbsp;<font color="#7ac142">www.inmunebio.com.</font></font></p><font style="MARGIN: 0px" face="Arial">&nbsp; <table id="pagebreak87bf58e2-b118-45f0-9564-03ef0b76a9ed" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table> <p style="MARGIN: 0px">&nbsp;</p></font><b><font face="Arial">INmune Bio Contact:&nbsp;</font></b> <p style="MARGIN: 0px"><font face="Arial">David Moss, CFO</font></p> <p style="MARGIN: 0px"><font face="Arial">(858) 964-3720</font></p><font color="#7ac142" face="Arial">DMoss@INmuneBio.com</font> <p style="MARGIN: 0px"><b><font face="Arial">Media Contact:&nbsp;</font></b></p> <p style="MARGIN: 0px"><font face="Arial">Antenna Group</font></p> <p style="MARGIN: 0px"><font face="Arial">Nechama Feuerstein</font></p> <p style="MARGIN: 0px"><font face="Arial">(201) 373-2228</font></p><font color="#7ac142" face="Arial">INmuneBio@AntennaGroup.com</font> <p style="MARGIN: 0px"><font face="Arial">&nbsp;</font></p><b><font face="Arial">Ascent Investor Relations:</font></b> <p style="MARGIN: 0px"><font face="Arial">Tina Xiao</font></p> <p style="MARGIN: 0px"><font face="Arial">President&nbsp;</font></p> <p style="MARGIN: 0px"><font face="Arial">(917) 609-0333</font></p><font color="#7ac142" face="Arial">tina.xiao@ascent-ir.com</font> <p style="MARGIN: 0px"><font face="Arial">&nbsp;</font></p><b><font face="Arial">Investors:</font></b> <p style="MARGIN: 0px"><font face="Arial">LHA Investor Relations</font></p> <p style="MARGIN: 0px"><font face="Arial">Miriam Weber Miller</font></p> <p style="MARGIN: 0px"><font face="Arial">Senior Vice President</font></p> <p style="MARGIN: 0px"><font face="Arial">(212) 838-3777</font></p><font color="#7ac142" face="Arial">mmiller@lhai.com</font> <font style="MARGIN: 0px" face="Arial"> <table id="pagebreakeeba9dc5-c6b0-4a18-ae1f-8048ec9b659d" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table> <p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
